Literature DB >> 21104134

Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals.

Ali A Dashti1, Mehrez M Jadaon.   

Abstract

Factor V Leiden mutation (FVL; G1691A) is an established risk factor for venous thromboembolic disorders. FVL was reported with high prevalence in Caucasians (1-15%) but was absent in non-Caucasians like Africans and Asians. Studies reported FVL in 5-27% of Arabs and non-Arabs living in the Middle Eastern countries northern to the Arabian Peninsula, but was almost absent in Arabs in the Arabian Peninsula itself. Kuwait is an Arabic country present on the northern border of the Arabian Peninsula, and Kuwaitis are originally from Saudi Arabia (Southern to Kuwait and within the Arabian Peninsula) or from Iran and Iraq (northern to Kuwait and the Arabian Peninsula). This study was conducted to study FVL in Kuwaitis in relation to their origin. Real-time PCR was performed on DNA samples of 285 apparently healthy Kuwaitis using specially designed primers and probes for FVL. There were 109 Kuwaitis of Iranian origin, 71 of Iraqi origin and 105 of Saudi origin. FVL was present in 7 and 5 Kuwaitis of Iranian and Iraqi origin, respectively. None of the Kuwaitis of Saudi origin had the mutation. Prevalence of FVL in Kuwaitis of Iranian (6.42%) and Iraqi (7.04%) origin were statistically different from prevalence in Kuwaitis of Saudi (0%) origin (P-value<0.05). No difference was found between females and males (P-value>0.6). In conclusion, FVL is present in Kuwaitis of Iranian or Iraqi origin only. Therefore, testing and providing genetic consultation for FVL may be needed in those Kuwaitis only which should save time, cost and efforts. However, this assumption should be confirmed by other studies and on larger number of cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21104134     DOI: 10.1007/s11033-010-0474-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

1.  Thrombophilic mutations in Iran.

Authors:  S Zeinali; F Duca; B Zarbakhsh; L Tagliabue; P M Mannucci
Journal:  Thromb Haemost       Date:  2000-02       Impact factor: 5.249

2.  High prevalence of factor V mutation (Leiden) in the Eastern Mediterranean.

Authors:  N Irani-Hakime; H Tamim; G Elias; R R Finan; J L Daccache; W Y Almawi
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

3.  High prevalence of factor V Leiden in healthy Jordanian Arabs.

Authors:  A Awidi; M Shannak; A Bseiso; M A Kailani; M A Kailani; N Omar; B Anshasi; N Sakarneh
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

4.  High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation?

Authors:  A Taher; I Khalil; A Shamseddine; F El-Ahdab; A Bazarbachi
Journal:  Thromb Haemost       Date:  2001-08       Impact factor: 5.249

5.  Prevalence of factor V Leiden in the Chinese population.

Authors:  C H Ho; W K Chau; H C Hsu; J P Gau; C M Chih
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  1999-12

6.  Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion.

Authors:  T M Johnson; S El-Defrawy; W G Hodge; B C Leonard; P J Kertes; D P Lillicrap
Journal:  Retina       Date:  2001       Impact factor: 4.256

7.  The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey.

Authors:  A Gürgey; L Mesci
Journal:  Turk J Pediatr       Date:  1997 Jul-Sep       Impact factor: 0.552

8.  Activated protein C resistance caused by a common factor V mutation has a single origin.

Authors:  B Zöller; A Hillarp; B Dahlbäck
Journal:  Thromb Res       Date:  1997-02-01       Impact factor: 3.944

9.  World distribution of factor V Leiden.

Authors:  D C Rees; M Cox; J B Clegg
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

10.  The Saudi Thrombosis and Familial Thrombophilia Registry. Design, rational, and preliminary results.

Authors:  Jalal N Saour; Mohammed M Shoukri; Layla A Mammo
Journal:  Saudi Med J       Date:  2009-10       Impact factor: 1.484

View more
  7 in total

1.  Prevalence of H1299R polymorphism in the Factor V gene among the Taif-Saudi Arabia population using polymerase chain reaction-reverse hybridization technique.

Authors:  Nabil Saied Awad; Adel El-Sayed El-Tarras
Journal:  Mol Biol Rep       Date:  2011-05-07       Impact factor: 2.316

2.  High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T.

Authors:  Ayman S Hussein
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

3.  Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.

Authors:  Mehrez M Jadaon
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-09-08       Impact factor: 2.576

4.  Case control study of the factor V Leiden and factor II G20210A mutation frequency in women with recurrent pregnancy loss.

Authors:  Majid Teremmahi Ardestani; Hossein Hadi Nodushan; Abbas Aflatoonian; Nasrin Ghasemi; Mohammad Hasan Sheikhha
Journal:  Iran J Reprod Med       Date:  2013-01

5.  Etiology of Recurrent Pregnancy Loss in Saudi Females.

Authors:  Ahlam A Al-Ghamdi; Sawsan F Makhashen
Journal:  Saudi J Med Med Sci       Date:  2016-08-11

6.  The prevalence of Factor V Leiden (Arg506Gln) mutation in King Khalid University Hospital patients, 2017-2019.

Authors:  Maram Al-Otaiby; Rahaf Althnayan; Alanoud Binmethem; Reema Bader AlEnezy; Munira Abdulrahman Alhadlg; Arjuwana Alaqeel; Sara H AlQahtani; Noman Ghufran; Abdulaziz A Alotaibi; Nada Alayed; Imran Ali Khan
Journal:  Nagoya J Med Sci       Date:  2021-08       Impact factor: 1.131

7.  Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population.

Authors:  Samieh Karimi; Majid Yavarian; Azadeh Azinfar; Minoo Rajaei; Maryam Azizi Kootenaee
Journal:  Iran J Reprod Med       Date:  2012-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.